Daiichi Sankyo (OTCMKTS:DSNKY) Sets New 52-Week Low - What's Next?

Key Points

• Daiichi Sankyo's ADR hit a new 52-week low of $15.57 on Friday, trading down about 10.4% with the last trade at $15.60 on volume of ~33,803 shares.
• The company beat EPS estimates for the quarter ($0.30 vs. $0.25) but missed revenue expectations ($3.65B vs. $3.88B); analysts project FY EPS of 1.04.
• Valuation and balance-sheet metrics show a market cap of $29.58B, P/E 14.33 and PEG 0.92, with low debt-to-equity (0.18) and healthy liquidity (quick ratio 1.85, current ratio 2.69), while the share price remains below its 50‑day ($18.39) and 200‑day ($21.12) moving averages.

Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report)'s share price reached a new 52-week low on Friday . The stock traded as low as $15.57 and last traded at $15.60, with a volume of 33803 shares trading hands. The stock had previously closed at $17.43.

Daiichi Sankyo Trading Down 10.4%

The stock has a market cap of $29.58 billion, a price-to-earnings ratio of 14.33, a price-to-earnings-growth ratio of 0.92 and a beta of -0.04. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.85 and a current ratio of 2.69. The company's 50 day simple moving average is $18.39 and its two-hundred day simple moving average is $21.12.

Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) last released its quarterly earnings data on Thursday, January 29th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.05. The firm had revenue of $3.65 billion for the quarter, compared to analyst estimates of $3.88 billion. Daiichi Sankyo had a net margin of 14.83% and a return on equity of 18.64%. Research analysts expect that Daiichi Sankyo Co., Ltd. - Sponsored ADR will post 1.04 EPS for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.